Table 3.
Criteria for Discontinuance of PCP Prophylaxis in Patients With Rheumatologic Disorders (n = 362)
| Criterion for Discontinuing PCP Prophylaxis | No. of Respondents (%)a |
|---|---|
| Concurrent with discontinuance of biologic DMARDs (TNFi, rituximab) | 50 (14) |
| Concurrent with discontinuance of nonbiologic DMARDs (methotrexate) | 26 (7) |
| Concurrent with discontinuance of cytotoxic agents (cyclophosphamide) | 45 (12) |
| When the daily steroid dose decreases below a certain level | 235 (65) |
| 0.5–10 mg | 70 (30) |
| 11–15 mg | 37 (16) |
| 16–20 mg | 123 (52) |
| 30 mg | 4 (2) |
| 40 mg | 2 (1) |
| 3 mo post-discontinuance of biologic DMARDs (TNFi, rituximab) | 64 (18) |
| 3 mo post-discontinuance of nonbiologic DMARDs (methotrexate) | 25 (7) |
| 3 mo post-discontinuance of cytotoxic agents (cyclophosphamide) | 54 (15) |
| When the CD4 count exceeds 200 cells/mm3 | 70 (19) |
| N/A, don’t make recommendations about discontinuance of prophylaxis | 29 (8) |
| Not sure | 44 (12) |
Abbreviations: DMARDs, disease-modifying antirheumatic drugs; PCP, Pneumocystis pneumonia; TNFi, tumor necrosis factor inhibitor.
aRespondents could select all that apply so totals may exceed 100%.